The estimated Net Worth of Brian Daniels is at least $6.26 million dollars as of 1 July 2014. Brian Daniels owns over 4,671 units of Cabaletta Bio Inc stock worth over $410,992 and over the last 17 years he sold CABA stock worth over $5,841,137. In addition, he makes $9,808 as Independent Director at Cabaletta Bio Inc.
Brian has made over 21 trades of the Cabaletta Bio Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 4,671 units of CABA stock worth $19,898 on 1 July 2014.
The largest trade he's ever made was selling 79,900 units of Cabaletta Bio Inc stock on 10 August 2012 worth over $2,534,428. On average, Brian trades about 10,939 units every 57 days since 2008. As of 1 July 2014 he still owns at least 96,477 units of Cabaletta Bio Inc stock.
You can see the complete history of Brian Daniels stock trades at the bottom of the page.
Dr. Brian Daniels M.D. serves as Independent Director of the Company. He joined Cabaletta’s Board of Directors in October 2018. Since 2018, he has been a partner at 5AM Ventures, where he was previously a venture partner from 2014 to 2018. From 2004 to 2014, Dr. Daniels held positions at Bristol-Myers Squibb, serving as senior vice president, global development and medical affairs from 2004 to 2014. Dr. Daniels also serves on the boards of directors of Spyryx Biosciences, Inc., Nohla Therapeutics Inc., RareCyte, Inc. and Novo Nordisk A/S and on the clinical advisory board of Aprea Therapeutics AB. He previously served on the board of directors of IDEAYA Biosciences, Inc. Dr. Daniels received his M.D. from Washington University in St. Louis and his B.S. and M.S. from Massachusetts Institute of Technology. He completed his residency in internal medicine at New York Hospital and a fellowship in rheumatology and immunology at University of California, San Francisco.
As the Independent Director of Cabaletta Bio Inc, the total compensation of Brian Daniels at Cabaletta Bio Inc is $9,808. There are 10 executives at Cabaletta Bio Inc getting paid more, with Anup Marda having the highest compensation of $1,528,630.
Brian Daniels is 60, he's been the Independent Director of Cabaletta Bio Inc since 2018. There are 1 older and 11 younger executives at Cabaletta Bio Inc. The oldest executive at Cabaletta Bio Inc is Richard Henriques, 64, who is the Independent Director.
Brian's mailing address filed with the SEC is C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104.
Over the last 5 years, insiders at Cabaletta Bio Inc have traded over $19,324,000 worth of Cabaletta Bio Inc stock and bought 1,500,545 units worth $13,043,398 . The most active insiders traders include Group, Llc Green Jeremy Red..., Ventures V, L.P.5 Am Opport... et James E Deerfield Mgmt Iv, .... On average, Cabaletta Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of $632,329. The most recent stock trade was executed by Gwendolyn Binder on 19 January 2024, trading 11,000 units of CABA stock currently worth $11,110.
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
Cabaletta Bio Inc executives and other stock owners filed with the SEC include: